Articles from Antidepressants

Primary tabs

Potential for Yet Another Totally Different Antidepressant - Psychology Today

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 15:52

Potential for Yet Another Totally Different Antidepressant  Psychology TodayCurrent pharmacologic treatments for depression may be relegated to second-tier treatments within the next decade. Why? Several classes of medications with ...

FDA Panel Backs Ketamine-like Drug for Depression - WebMD

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 15:24

FDA Panel Backs Ketamine-like Drug for Depression  WebMDDespite the panel's approval, two of five key studies of esketamine failed to meet their primary goals. When taking esketamine, some patients experienced ...

VistaGen Therapeutics (VTGN) Granted US Patent Related to Methods for Treating Depression with PH10 - StreetInsider.com

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 13:36

VistaGen Therapeutics (VTGN) Granted US Patent Related to Methods for Treating Depression with PH10  StreetInsider.comGet instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. VistaGen Therapeutics (NASDAQ: VTGN) today ...

VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10 - P&T Community

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 13:32

VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10  P&T CommunitySOUTH SAN FRANCISCO, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company ...

VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10 - The Bakersfield Californian

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 13:30

VistaGen Therapeutics Receives Notice of Allowance for U.S. Patent for Treatment of Depression with PH10  The Bakersfield CalifornianSOUTH SAN FRANCISCO, Calif., Feb. 13, 2019 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company ...

Man, 56, took his own life after starting new medication - Horncastle News

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 12:35

Man, 56, took his own life after starting new medication  Horncastle NewsThe family of a 56-year-old man who took his own life have blamed an antidepressant drug prescribed to him less than two weeks earlier.

Esketamine floats past adcom vote - Vantage

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 12:00

Esketamine floats past adcom vote  VantageJohnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.

FDA panel backs J&J's new-class antidepressant - PMLiVE

Submitted by Anonymous (not verified) on Wed, 02/13/2019 - 11:19

FDA panel backs J&J's new-class antidepressant  PMLiVEJohnson & Johnson could be just weeks away from approval of the first new drug class for depression in decades, giving a new option for patients with severe, ...

Pages